Introduction: Skin injury and wound healing is an inevitable event during lifetime. However, several complications may hamper the regeneration of the cutaneous tissue and lead to a chronic profile that prolongs patient recovery. Platelet-rich plasma is rising as an effective and safe alternative to the management of wounds. However, this technology presents some limitations such as the need for repeated blood extractions and health-care interventions. Objective: The aim of this study was to assess the use of an endogenous and storable topical serum (ES) derived from plasma rich in growth factors promoting wound healing, and to obtain preliminary data regarding its clinical and experimental effect over ulcerated skin models and patient care. Methods: Human dermal fibroblast and 3D organotypic ulcerated skin models were used to assess ES over the main mechanisms of wound healing including cell migration, edge contraction, collagen synthesis, tissue damage, extracellular matrix remodeling, cell death, metabolic activity, and histomorphometry analysis. Additionally, 4 patients suffering from skin wounds were treated and clinically assessed. Results: ES promoted dermal fibroblast migration, wound edge contraction, and collagen synthesis. When topically applied, ES increased collagen and elastin deposition and reduced tissue damage. The interstitial edema, structural integrity, and cell activity were also maintained, and apoptotic levels were reduced. Patients suffering from hard-to-heal wounds of different etiologies were treated with ES, and the ulcers healed completely within few weeks with no reported adverse events. Conclusion: This preliminary study suggests that ES might promote cutaneous wound healing and may be useful for accelerating the re-epithelization of skin ulcers.

1.
Velnar
T
,
Bailey
T
,
Smrkolj
V
.
The wound healing process: an overview of the cellular and molecular mechanisms
.
J Int Med Res
.
2009
;
37
:
1528
42
. .
2.
Guest
JF
,
Ayoub
N
,
McIlwraith
T
,
Uchegbu
I
,
Gerrish
A
,
Weidlich
D
,
Health economic burden that wounds impose on the National health service in the UK
.
BMJ Open
.
2015
;
5
:
e009283
. .
3.
Mandla
S
,
Davenport Huyer
L
,
Radisic
M
.
Review: multimodal bioactive material approaches for wound healing
.
APL Bioeng
.
2018
;
2
:
021503
. .
4.
Oliveira
A
,
Simões
S
,
Ascenso
A
,
Reis
CP
.
Therapeutic advances in wound healing
.
J Dermatolog Treat
.
2020
:
1
21
. .
5.
Shen
Z
,
Zheng
S
,
Chen
G
,
Li
D
,
Jiang
Z
,
Li
Y
,
Efficacy and safety of platelet rich plasma in treating cutaneous ulceration: a meta analysis of randomized controlled trials
.
J Cosmet Dermatol
.
2019
;
18
:
495
507
.
6.
Anitua
E
,
Pino
A
,
Orive
G
.
Opening new horizons in regenerative dermatology using platelet-based autologous therapies
.
Int J Dermatol
.
2017
;
56
:
247
51
. .
7.
Anitua
E
,
Troya
M
,
Pino
A
.
A novel protein-based autologous topical serum for skin regeneration
.
J Cosmet Dermatol
.
2020
;
19
:
705
13
. .
8.
Anitua
E
,
Alkhraisat
MH
,
Orive
G
.
Perspectives and challenges in regenerative medicine using plasma rich in growth factors
.
J Control Release
.
2012
;
157
:
29
38
. .
9.
Sánchez
M
,
Fiz
N
,
Azofra
J
,
Usabiaga
J
,
Aduriz Recalde
E
,
Garcia Gutierrez
A
,
A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis
.
Arthroscopy
.
2012
;
28
:
1070
8
. .
10.
Anitua
E
,
Sanchez
M
,
Nurden
AT
,
Zalduendo
M
,
de la Fuente
M
,
Orive
G
,
Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities
.
J Biomed Mater Res A
.
2006
;
77
:
285
93
. .
11.
Anitua
E
,
Begoña
L
,
Orive
G
.
Treatment of hemimandibular paresthesia in a patient with bisphosphonate-related osteonecrosis of the jaw (BRONJ) by combining surgical resection and PRGF-Endoret
.
Br J Oral Maxillofac Surg
.
2013
;
51
:
e272
4
. .
12.
Anitua
E
,
Muruzabal
F
,
Tayebba
A
,
Riestra
A
,
Perez
VL
,
Merayo-Lloves
J
,
Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies
.
Acta Ophthalmol
.
2015
;
93
:
e605
14
. .
13.
Anitua
E
.
Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants
.
Int J Oral Maxillofac Implants
.
1999
;
14
:
529
35
.
14.
Anitua
E
,
Aguirre
JJ
,
Algorta
J
,
Ayerdi
E
,
Cabezas
AI
,
Orive
G
,
Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers
.
J Biomed Mater Res Part B Appl Biomater
.
2008
;
84
:
415
21
. .
15.
Muñoz
V
,
Martinez
C
,
Echevarria
B
,
Fernández
MI
,
Pino
A
,
Anitua
E
.
Biological approach for managing severe gunshot wounds: a case report
.
J Wound Ostomy Continence Nurs
.
2018
;
45
:
359
63
. .
16.
Anitua
E
,
Pino
A
.
The management of postsurgical wound complications with plasma rich in growth factors: a preliminary series
.
Adv Skin Wound Care
.
2020
;
33
:
202
8
. .
17.
Anitua
E
,
Pino
A
,
Orive
G
.
Plasma rich in growth factors promotes dermal fibroblast proliferation, migration and biosynthetic activity
.
J Wound Care
.
2016
;
25
:
680
7
. .
18.
George Broughton
I
,
Janis
JE
,
Attinger
CE
.
The basic science of wound healing
.
Plast Reconstr Surg
.
2006
;
117
:
12S
34S
.
19.
Dawe
R
.
An overview of the cutaneous porphyrias
.
F1000Res
.
2017
;
6
:
1906
. .
20.
Frykberg
RG
,
Banks
J
.
Challenges in the treatment of chronic wounds
.
Adv Wound Care
.
2015
;
4
:
560
82
. .
21.
Baldo
BA
.
Side effects of cytokines approved for therapy
.
Drug Saf
.
2014
;
37
:
921
43
. .
22.
Anitua
E
,
Pino
A
,
Jaen
P
,
Orive
G
.
Plasma rich in growth factors enhances wound healing and protects from photo-oxidative stress in dermal fibroblasts and 3D skin models
.
Curr Pharm Biotechnol
.
2016
;
17
:
556
70
. .
23.
Abe
M
,
Yokoyama
Y
,
Ishikawa
O
.
A possible mechanism of basic fibroblast growth factor-promoted scarless wound healing: the induction of myofibroblast apoptosis
.
Eur J Dermatol
.
2012
;
22
:
46
53
. .
24.
Grinnell
F
.
Fibroblasts, myofibroblasts, and wound contraction
.
J Cell Biol
.
1994
;
124
:
401
4
. .
25.
Cho
JW
,
Kim
SA
,
Lee
KS
.
Platelet-rich plasma induces increased expression of G1 cell cycle regulators, type I collagen, and matrix metalloproteinase-1 in human skin fibroblasts
.
Int J Mol Med
.
2012
;
29
:
32
6
. .
26.
Kim
MS
,
Song
HJ
,
Lee
SH
,
Lee
CK
.
Comparative study of various growth factors and cytokines on type I collagen and hyaluronan production in human dermal fibroblasts
.
J Cosmet Dermatol
.
2014
;
13
:
44
51
. .
27.
Anitua
E
,
Pino
A
,
Orive
G
.
Plasma rich in growth factors inhibits ultraviolet B induced photoageing of the skin in human dermal fibroblast culture
.
Curr Pharm Biotechnol
.
2016
;
17
(
12
):
1068
78
. .
28.
Hwang
YP
,
Kim
HG
,
Han
EH
,
Choi
JH
,
Park
BH
,
Jung
KH
,
N-Acetylglucosamine suppress collagenases activation in ultraviolet B-irradiated human dermal fibroblasts: involvement of calcium ions and mitogen-activated protein kinases
.
J Dermatol Sci
.
2011
;
63
:
93
103
. .
29.
Anitua
E
,
Troya
M
,
Goñi
F
,
Gómez
P
,
Tierno
R
,
Pino
A
.
A novel autologous topical serum based on plasma rich in growth factors technology counteracts ultraviolet light-derived photo-oxidative stress
.
Skin Pharmacol Physiol
.
2020
;
33
(
3
):
1
15
.
30.
Anitua
E
,
de la Fuente
M
,
del Olmo Aguado
S
,
Suarez Barrio
C
,
Merayo Lloves
J
,
Muruzabal
F
.
Plasma rich in growth factors reduces blue light induced oxidative damage on retinal pigment epithelial cells and restores their homeostasis by modulating vascular endothelial growth factor and pigment epithelium derived factor expression
.
Clin Exp Ophthalmol
.
2020
. 48(6):830–8.
31.
Chen
J
,
Jiao
D
,
Zhang
M
,
Zhong
S
,
Zhang
T
,
Ren
X
,
Concentrated growth factors can inhibit photoaging damage induced by ultraviolet A (UVA) on the human dermal fibroblasts in vitro
.
Med Sci Monit
.
2019
;
25
:
3739
. .
32.
Kim
JM
,
Choo
JE
,
Kim
KN
,
Kim
YS
.
Potential protective effects of rhEGF against ultraviolet A irradiation-induced damages on human fibroblasts
.
Clin Cosmet Investig Dermatol
.
2018
;
11
:
505
. .
33.
Anitua
E
,
Prado
R
,
Azkargorta
M
,
Rodriguez Suárez
E
,
Iloro
I
,
Casado Vela
J
,
High throughput proteomic characterization of plasma rich in growth factors (PRGF–Endoret) derived fibrin clot interactome
.
J Tissue Eng Regen Med
.
2015
;
9
:
E1
E12
.
34.
Descalzi
F
,
Ulivi
V
,
Cancedda
R
,
Piscitelli
F
,
Luongo
L
,
Guida
F
,
Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism
.
Tissue Eng Part A
.
2013
;
19
:
2120
9
. .
35.
Anitua
E
,
Zalduendo
M
,
Troya
M
,
Padilla
S
,
Orive
G
.
Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties
.
PloS One
.
2015
;
10
:
e0121713
. .
36.
Anitua
E
,
Alonso
R
,
Girbau
C
,
Aguirre
J
,
Muruzabal
F
,
Orive
G
.
Antibacterial effect of plasma rich in growth factors (PRGF® Endoret®) against Staphylococcus aureus and Staphylococcus epidermidis strains
.
Clin Exp Dermatol
.
2012
;
37
:
652
7
.
37.
Chen
L
,
Wang
C
,
Liu
H
,
Liu
G
,
Ran
X
.
Antibacterial effect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro
.
J Diabetes Res
.
2013
;
2013
:
269527
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.